NeoGenomics, Inc. reports developments in oncology diagnostic testing, cancer genetics and information services. The company serves oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through cancer-focused laboratory testing, professional interpretation, clinical trial and research services, validation laboratory services and oncology data solutions.
Recurring news themes include clinical revenue trends, next-generation sequencing growth, reimbursement and coverage decisions, and additions to the company’s testing menu. Updates also cover products such as PanTracer LBx, PanTracer Tissue and RaDaR ST, electronic health record access through Epic Aura, research presentations using Oncology Data Solutions, and the operation of CAP-accredited and CLIA-certified laboratory capabilities in the United States and the United Kingdom.
NeoGenomics, Inc. (NASDAQ: NEO) has appointed Chris Smith as CEO, effective August 15, 2022. Smith, previously CEO of Ortho Clinical Diagnostics, brings extensive experience in the diagnostic industry. He is expected to lead NeoGenomics in navigating the growing oncology market. Alongside him, Lynn Tetrault will transition to the role of independent Chair of the Board. The company operates globally with a focus on cancer genetics testing, aiming to enhance patient care and treatment innovation.
NeoGenomics, Inc. (NASDAQ: NEO) announced it will release its second quarter 2022 financial results on August 9, 2022. A conference call will be held at 8:30 AM EDT that day to discuss the results. Interested parties can join by calling (877) 545-0523 for domestic or (973) 528-0016 for international access. The call will also be available for replay until August 23, 2022. NeoGenomics specializes in cancer genetics testing and services, and operates certified laboratories across the U.S. and internationally.
NeoGenomics, Inc. (NASDAQ: NEO) announces new data from its subsidiary Inivata, supporting the RaDaRTM assay for detecting minimal residual disease (MRD) in high-risk HR+ HER2- breast cancer patients. The CHiRP study revealed that 10% of patients had positive MRD results, with ctDNA identified a median of one year before distant metastasis. The study emphasizes RaDaR's potential for early tumor recurrence detection, potentially leading to timely intervention. The findings were published in the Journal of Clinical Oncology and were presented at the ASCO Annual Meeting.
NeoGenomics, Inc. (NASDAQ: NEO) announced its participation in several institutional investor conferences. Management will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 12:20 pm ET, with a live webcast available on the company's website. Additionally, they will conduct investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. NeoGenomics specializes in cancer genetics testing and services, emphasizing patient support and compliance with data protection laws.
NeoGenomics, Inc. has achieved CAP certification for its Suzhou laboratories with zero deficiencies, enhancing its capabilities in oncology drug development for clients in China. This certification will benefit global pharmaceutical partners by facilitating clinical trials from early discovery research to drug development. The company has established partnerships with local CROs and offers a variety of testing services including next-generation sequencing. The strategic move aims to strengthen NeoGenomics' position in the growing biopharma sector.
NeoGenomics, Inc. (NASDAQ:NEO) announced the appointment of Lynn Tetrault as Chair of the Board and Interim CEO effective May 12, 2022, following the previous CEO's resignation. Tetrault, who has been with the company since 2015, will ensure operational continuity during the search for a permanent CEO. The company also disclosed the departure of Douglas Brown, Chief Strategy and Corporate Development Officer, on May 27. The firm remains focused on enhancing operational efficiency and providing extensive cancer genetic testing services.
NeoGenomics (NASDAQ: NEO) announced that its subsidiary Inivata will present new data on its RaDaR assay for minimal residual disease detection at the ASCO Annual Meeting from June 3-7, 2022. The presentations will include three posters and one oral presentation showcasing RaDaR's sensitivity and specificity across tumor types, along with data on the InVisionFirst-Lung test for advanced lung cancer. The advancements highlight the potential of these assays to transform cancer care.
NeoGenomics, Inc. (NASDAQ: NEO) announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata, effective May 23, 2022, following the departure of Dr. Clive Morris. Vishal brings over 20 years of experience in somatic diagnostics, previously serving as President of Oncology at Invitae. The transition aims to enhance leadership in precision oncology, particularly with the upcoming launch of the RaDaR assay. Separately, Dr. Gina Wallar resigned as President of Pharma Services, with Jennifer Rose taking interim responsibilities.
NeoGenomics (NASDAQ: NEO) announced its participation in the BofA 2022 Healthcare Conference on May 12, 2022, in Las Vegas, with a fireside chat scheduled at 9:20 AM PT. Senior management will discuss the company's cancer-focused genetic testing services and operational strategies. The event will be webcasted live and accessible via the company’s website. NeoGenomics specializes in comprehensive oncology services and is dedicated to connecting patients with innovative therapies and clinical trials.
NeoGenomics (NASDAQ:NEO) reported its first-quarter results for 2022, showing a 1% increase in consolidated revenue to $117 million. The Clinical Services segment grew by 2% to $99 million, while Pharma Services revenue fell 4% to $18 million. Gross profit decreased by 8% to $38.2 million, resulting in a net loss of $49 million. Operating expenses surged 59% to $34 million, mainly due to acquisitions. Despite challenges, the company aims to improve performance and is actively searching for a new CEO.